Targeted Genetics' Board of Directors Appoints B.G. Susan Robinson, President and CEO, as Director
17 11월 2008 - 9:30PM
Marketwired
Targeted Genetics Corporation (NASDAQ: TGEN) today announced that
its Board of Directors appointed B.G. Susan Robinson, President and
Chief Executive Officer, as a member of the Board of Directors
effective November 14, 2008. Separately, the Board accepted the
resignation of H. Stewart Parker as a Director effective November
14, 2008.
As previously announced on November 10, 2008, the Board of
Directors appointed Ms. Robinson as president and chief executive
officer of the Company and Ms. Parker resigned from her position as
the president and chief executive officer of Targeted Genetics,
both effective November 6, 2008. Ms. Parker began her service as a
director of Targeted Genetics in 1989.
About Targeted Genetics Corporation
Targeted Genetics Corporation is a biotechnology company
committed to the development of innovative, targeted molecular
therapies for the prevention and treatment of acquired and
inherited diseases with significant unmet medical need. Targeted
Genetics' proprietary Adeno-Associated Virus (AAV) technology
platform allows it to deliver genes that encode proteins to
increase gene function or RNAi to decrease or silence gene
function. Targeted Genetics' product development efforts target
inflammatory arthritis, AIDS prophylaxis, congestive heart failure,
Huntington's disease and Leber's congenital amaurosis. To learn
more about Targeted Genetics, visit Targeted Genetics' website at
www.targetedgenetics.com.
Safe Harbor Statement under the Private Securities Litigation
Reform Act of 1995:
This release contains forward-looking statements regarding the
Company's liquidity and financial resources, its ability to fund
ongoing and future operations and its business strategy and product
development, including statements regarding the Company's ability
to extend its cash horizon, advance its platform and product
pipeline and create value from its product candidates and other
statements about the Company's plans, objectives, intentions and
expectations. These statements involve current expectations,
forecasts of future events and other statements that are not
historical facts. Inaccurate assumptions and known and unknown
risks and uncertainties can affect the accuracy of forward-looking
statements. Factors that could affect actual future events or
results include, but are not limited to, the risk that the Company
will run out of cash earlier than expected, the risk that the
Company will not be able to raise capital or secure other financial
resources in the near term, the risk that the Company's research
and development programs are not successful or are delayed or
terminated, the risk that payments anticipated by the Company under
product development collaborations and contracts are not earned or
received when expected or at all, and the risk that the Company
will not be able to maintain its listing on the NASDAQ Capital
Market , as well as other risk factors described in its filings
with the Securities and Exchange Commission (SEC), including in
"Item 1A. Risk Factors" in the Company's most recent quarterly
report on Form 10-Q for the quarter ended September 30, 2008 filed
with the SEC. You should not rely unduly on these forward-looking
statements, which apply only as of the date of this release. The
Company undertakes no duty to publicly announce or report revisions
to these statements as new information becomes available that may
change the Company's expectations.
Media Contact: Stacie D. Byars WeissComm Partners 206.660.2588
Email Contact
Tecogen (NASDAQ:TGEN)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Tecogen (NASDAQ:TGEN)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024